Phase II trial of high-dose cisplatin plus ifosfamide as first-line followed by carboplatin as second-line treatment in epithelial ovarian carcinoma

Gynecologic Oncology

Volumn 66, Issue 1, 1997, Pages 66-70

  Strauss, Gitte ^a   Lund, Birthe ^a   Hansen, Mogens ^b   Hansen, Heine H ^a  

^a University of Copenhagen   (Denmark)

^b HILLERØD HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; IFOSFAMIDE; MESNA;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; EPISTAXIS; FEMALE; HUMAN; LEUKOPENIA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVARY CARCINOMA; PETECHIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SECOND LOOK SURGERY; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 0031193964     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4733     Document Type: Article

References (21)

1. Lund B, Hansen M, Hansen O P. High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease. J Clin Oncol. 7:1989;1469-1473.
2. Lund B, Hansen M, Hansen O P, Hansen H H. Combined high-dose carboplatin and cisplatin, and ifosfamide in previously untreated ovarian cancer patients with residual disease. J Clin Oncol. 8:1990;1226-1230.
3. WHO Handbook for Reporting Results of Cancer Treatment. 1979;WHO, Geneva.
4. Armitage P. Statistical methods in medical research. 1971;Blackwell, New York.
5. Neijt J P, ten Bokkel Huinik W W, van der Burg M EL. Long-term survival in ovarian cancer. Eur J Cancer. 27:1991;1367-1372.
6. Neijt J P, ten Bokkel Huinik W W, van der Burg M EL. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 vs CP) in advanced ovarian carcinoma. J Clin Oncol. 5:1987;1157-1168.
7. Omura G A, Bundy B N, Berek J S. Randomised trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol. 7:1989;457-465.
8. Lancet. 2:1987;353-359.
9. Dobbs S P, Gribbin C, Chan S Y. Second-line treatment with ifosfamide and carboplatin in patients with ovarian carcinoma relapsing after treatment with carboplatin. Eur J Cancer. 30A:1994;30-33.
10. van der Burg M EL, Hoff A M, van Lent M. Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy. Eur J Cancer. 27:1991;248-250.
11. Markman M, Rothman R, Hakes T. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 9:1991;389-393.
12. Sutton G. Ifosfamide and mesna in epithelial ovarian carcinoma. Gynecol Oncol. 51:1993;104-108.
13. Markman M, Hakes T, Reichman B. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease. J Clin Oncol. 10:1992;243-248.
14. Kjorstad K, Harris A, Bertelsen K. A multicenter phase II study of carboplatin in advanced ovarian carcinoma. Ann Oncol. 3:1992;217-222.
15. Gore M E, Fryatt I, Wiltshaw E. Cisplatin/carboplatin cross-resistance in ovarian cancer. Br J Cancer. 60:1989;767-769.
16. Ozols R F, Ostchega Y, Curt G. High-dose carboplatin in refractory ovarian cancer patients. J Clin Oncol. 5:1987;197-201.
17. Bertelsen K, Jakobsen A, Stroyer J. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: A Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol. 49:1993;30-36.
18. Hakes T B, Chalas E, Hoskins W J. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin and cisplatin in advanced ovarian carcinoma. Gynecol Oncol. 45:1992;284-289.
19. Gershenson D M, Mitchell M F, Atkinson N. The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal ovarian cancer: "Maintainance" therapy reconsidered. Gynecol Oncol. 47:1992;7-13.
20. Kaye S B, Paul J, Cassidy J. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol. 14:1996;2113-2119.
21. McGuire W P, Hoskins W J, Brady M F. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:1996;1-6.